Table 1.
Measured Parameter | Unfractured | 1.5 weeks post fracture | 3 weeks post fracture | |||
---|---|---|---|---|---|---|
| ||||||
Control (n=6) | Hox11 mutant (n=8) | Control (n=5) | Hox11 mutant (n=8) | Control (n=5) | Hox11 mutant (n=6) | |
Callus Volume (mm3) | 0.45 (0.03) | 0.52 (0.04)* | 1.81 (0.45) | 2.75 (0.72)* | 1.74 (0.22) | 1.59 (0.50) |
Bone Volume (mm3) | 0.32 (0.01) | 0.35 (0.03)* | 0.52 (0.13) | 0.78 (0.22)* | 0.57 (0.08) | 0.57 (0.21) |
BV/TV (%) | .71 (0.02) | 0.67 (0.02) | .32 (0.18) | 0.28 (0.03) | 0.33 (0.05) | 0.35 (0.05) |
BMD (mg/cc) | 839.6 (40.7) | 740.2 (61.8) | 486.0 (173.2) | 424.1 (101.1) | 511.3 (30.4) | 480.2 (77.5) |
BMC (mg) | .36 (0.01) | 0.39 (0.05) | 0.82 (0.15) | 1.07 (0.31) | 0.89 (0.08) | 0.78 (0.32) |
TMD (mg/cc) | 977.0 (32.0) | 905.6 (85.4) | 935.3 (101.8) | 860.7 (101.4) | 838.0 (31.3) | 792.5 (74.3) |
| ||||||
Measured Parameter | 6 weeks post fracture | 12 weeks post fracture | 21 weeks post fracture | |||
| ||||||
Control (n=5) | Hox11 mutant (n=6) | Control (n=5) | Hox11 mutant (n=4) | Control | Hox11 mutant (n=5) | |
| ||||||
Callus Volume (mm3) | 1.45 (0.25) | 1.61 (0.62) | 0.99 (0.12) | 1.52 (0.27)* | ND | 1.49 (0.16)* |
Bone Volume (mm3) | 0.79 (0.13) | 0.81 (0.28) | 0.63 (0.10) | 0.93 (0.04)* | ND | 0.86 (0.06)* |
BV/TV (%) | 0.55 (0.07) | 0.51 (0.05) | 0.64 (0.04) | 0.63 (0.09) | ND | 0.58 (0.04) |
BMD (mg/cc) | 664.3 (83.7) | 606.4 (60.2) | 796.2 (49.3) | 817.7 (104.3) | ND | 751.2 (24.3) |
BMC (mg) | 0.96 (0.17) | 0.97 (0.34) | 0.79 (0.13) | 1.22 (0.07)* | ND | 1.09 (0.12)* |
TMD (mg/cc) | 896.8 (48.6) | 866.9 (37.1) | 1036.2 (26.4) | 1054.0 (72.6) | ND | 983.3 (57.1) |
ND, no data collected. Parameters measured include callus volume, total bone volume, bone volume fraction (BV/TV), bone mineral density (BMD), bone mineral content (BMC), and tissue mineral density (TMD). Statistical analyses carried out by Students' T-test;
= p<0.05.